Article
Vemurafenib: the road to personalized medicine in melanoma.
Drugs of today (Barcelona, Spain : 1998) - 1 Feb 2012
Amaria R N, Lewis K D, Jimeno A
Abstract excerpt
Advanced melanoma has a poor prognosis due to its resistance to traditional chemotherapeutics, leading to the search for alternative treatment approaches. With the finding that approximately 50% of melanomas harbor an activating mutation in the serine/threonine-protein kinase B-raf gene (BRAF), inhibition of mutated B-raf represented an attractive and innovative focus for the development of novel targeted therapy...
Topics
- Clinical Trials as Topic
- Drug Resistance, Neoplasm
- Humans
- Indoles
- Melanoma
- Mutation
- Precision Medicine
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins B-raf
- Sulfonamides
- Vemurafenib